# IL-2 mutein (mRNA-6231)

*Last program update: May 6, 2021*

<table>
<thead>
<tr>
<th>Modality</th>
<th>ID #</th>
<th>Program Indication</th>
<th>Preclinical development</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3 and commercial</th>
<th>Moderna rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td>mRNA-1944</td>
<td>Antibody against Chikungunya virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide, DARPA funded</td>
</tr>
<tr>
<td>mRNA</td>
<td>mRNA-0184</td>
<td>Relaxin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
<tr>
<td>mRNA</td>
<td>mRNA-6981</td>
<td>PD-L1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
<tr>
<td>mRNA</td>
<td>mRNA-6231</td>
<td>IL-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
</tbody>
</table>

**Systemic secreted & cell surface therapeutics**
IL-2 (mRNA-6231) – long acting mutein

**mRNA-encoded IL-2 modified for the expansion of regulatory T cells**

- Modified IL-2 is longer acting and more selective for the high affinity IL-2 receptor which is expressed mainly by regulatory T cells
- First intended subcutaneous administration of the LNP successfully used in a clinical trial for our mRNA-encoded antibody, mRNA-1944
- Recombinant IL-2 based therapeutics are being clinically evaluated for a wide range of autoimmune conditions
IL-2 mutein (mRNA-6231)
Preclinical data – demonstrates preferential expansion of Treg in NHP

NHP were dosed subcutaneously with a single dose of mRNA-6231 and T cells in the peripheral blood were monitored on days 1, 3, 5, 8, and 14.

1. Percent either Treg or activated CD8 out of total CD4+ or CD8+ respectively
2. Treg defined as CD3+CD4+Foxp3+, increase represents an average over 4 animals, maximum is day 8 post-dosing
3. Activated CD8+ defined as CD3+CD8+ CD25+

Treg increased ~12 fold at their peak
Activated CD8+ T cells did not significantly increase over baseline
Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.